Stock listing

Frankfurt:7JK EQL Pharma AB Aktie

German listing (Frankfurt) of EQL Pharma AB · home listing Stockholm:EQL

Follow EQL Pharma AB into a list and get an email when it puts out news.

Share price · FWB:7JK

€1.92 EUR -0.01 (-0.6%)

Close on Nov 20, 2026

Past year -52.2% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€1.90 – €1.92 EURNov 20, 2026
Market cap
€56.76M EURAt the close on Nov 20, 2026 · price × 29.53M shares outstanding
52-week range
€1.65 – €6.21 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
EQL Pharma AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:EQL · Home21.65 SEK-0.60 (-2.7%)26,45122.9022.9021.2022.25Close on Nov 20, 2026
Frankfurt:7JK€1.922 EUR-0.012 (-0.6%)—€1.90€1.922€1.90€1.934Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:7JK · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€2.254-0.048-2.1%€2.191€2.285€2.1760
€2.302+0.287+14.2%€2.307€2.416€2.2810
€2.015+0.204+11.3%€1.852€2.043€1.8450
€1.811+0.003+0.2%€1.832€1.832€1.8110
€1.808+0.082+4.8%€1.758€1.816€1.7480
€1.726+0.046+2.7%€1.683€1.726€1.6670
€1.68-0.002-0.1%€1.688€1.69€1.6760
€1.682+0.013+0.8%€1.693€1.694€1.6720
€1.669-0.043-2.5%€1.677€1.677€1.650
€1.712-0.007-0.4%€1.741€1.75€1.7070
€1.719-0.023-1.3%€1.731€1.736€1.7180
€1.742+0.001+0.1%€1.749€1.749€1.7320
€1.741-0.015-0.9%€1.736€1.75€1.7160
€1.756-0.093-5.0%€1.815€1.856€1.7370
€1.849-0.067-3.5%€1.90€1.923€1.8390
€1.916-0.024-1.2%€1.903€1.919€1.900
€1.94-0.005-0.3%€1.928€1.946€1.9120
€1.945+0.003+0.2%€1.954€1.966€1.9420
€1.942+0.002+0.1%€1.901€1.962€1.8980
€1.94+0.008+0.4%€1.826€1.97€1.8150
€1.932+0.054+2.9%€1.892€1.947€1.8760
€1.878-0.145-7.2%€2.058€2.058€1.8730
€2.023-0.01-0.5%€2.022€2.033€2.0170
€2.033+0.059+3.0%€2.017€2.05€1.9990
€1.974-0.184-8.5%€1.938€1.978€1.9310
€2.158+0.205+10.5%€1.99€2.207€1.9890
€1.953-0.021-1.1%€1.955€1.968€1.9530
€1.974-0.01-0.5%€1.966€1.986€1.9550
€1.984+0.004+0.2%€1.976€1.986€1.9670
€1.98+0.003+0.2%€2.007€2.012€1.9690
€1.977-0.003-0.2%€1.98€2.013€1.9770
€1.98-0.03-1.5%€1.984€1.985€1.9790
€2.01+0.003+0.1%€2.01€2.01€1.9960
€2.007-0.037-1.8%€2.012€2.012€1.9980
€2.044-0.125-5.8%€2.13€2.143€2.0270
€2.169+0.013+0.6%€2.155€2.17€2.1230
€2.156-0.005-0.2%€2.158€2.158€2.1450
€2.161-0.09-4.0%€2.24€2.245€2.1550
€2.251-0.002-0.1%€2.25€2.251€2.2440
€2.253-0.023-1.0%€2.258€2.271€2.2330
€2.276-0.036-1.6%€2.292€2.31€2.2740
€2.312-0.041-1.7%€2.325€2.325€2.3090
€2.353-0.066-2.7%€2.406€2.418€2.3510
€2.419+0.047+2.0%€2.426€2.427€2.3820
€2.372+0.103+4.5%€2.302€2.373€2.2980
€2.269+0.019+0.8%€2.277€2.30€2.2460
€2.25+0.052+2.4%€2.197€2.254€2.1920
€2.198-0.098-4.3%€2.252€2.266€2.1880
€2.296-0.024-1.0%€2.314€2.321€2.2860
€2.32+0.073+3.2%€2.261€2.324€2.2540
€2.247-0.119-5.0%€2.231€2.25€2.1860
€2.366-0.091-3.7%€2.444€2.451€2.3620
€2.457+0.087+3.7%€2.394€2.467€2.3850
€2.37+0.008+0.3%€2.375€2.381€2.3630
€2.362+0.062+2.7%€2.347€2.364€2.3280
€2.30-0.007-0.3%€2.239€2.313€2.2220
€2.307-0.011-0.5%€2.364€2.384€2.2850
Ticker
Frankfurt:7JK
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All EQL Pharma AB news

EQL Pharma AB on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
1 in the last 12 months · 2 in all · newest Jul 27, 2026 · oldest 2025
Calls
6 calls with a replay · 6 with a transcript · latest Sep 12, 2023
Decks
4 decks · latest Nov 5, 2026

Where EQL Pharma AB is listed

ListingExchangeCountryCurrency
Stockholm:EQL · Home listingStockholmSwedenSEK
gettex:7JKgettexGermanyEUR
LS Exchange:A12AZYLS ExchangeGermanyEUR
Turquoise:EQLSTurquoiseUnited KingdomSEK
Lang & Schwarz:A12AZYLang & SchwarzGermanyEUR
Stuttgart:7JKStuttgartGermanyEUR
Dusseldorf:7JKDusseldorfGermanyEUR
Frankfurt:7JK · This pageFrankfurtGermanyEUR
Munich:7JKMunichGermanyEUR

Valuation

P/E 51.0× against a median of 8.7×: the highest of 8 Pharmaceuticals companies shown. Statements: Year to Mar 31, 2026 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
578.2M SEK
P/E
51.0×
EV/sales
1.3×
EV/EBITDA
8.1×
Price/book
2.5×
Gross margin
37.6%
Operating margin
11.3%
Net margin
2.9%
Debt to equity
0.0×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
EQL Pharma AB · OMXSTO:EQLUS$62.53MUS$56.55M51.0×1.3×8.1×2.5×2.9%0.0×n/a
Wanbury Limited · NSE:WANBURYUS$67.68MUS$67.68M11.2×1.0×6.4×4.3×8.6%0.0×n/a
Euroapi SA · EURONEXT:EAPIUS$67.31MUS$343.1Mn/a0.4×31.6×0.1×−24.9%0.5×n/a
Bangkok Lab and Cosmetic Public Company Limited · SET:BLCUS$66.78MUS$65.27M16.6×1.4×9.0×1.4×8.4%0.0×n/a
JW Shinyak Corp. · KRX:067290US$66.62MUS$63.79M8.7×1.0×6.9×2.2×12.1%0.0×n/a
Laboratorios Richmond SACIF Class B · BCBA:RICHUS$65.34MUS$173.1M8.4×2.1×7.5×0.9×9.3%1.5×n/a
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A · TWSE:1762US$63.36MUS$76.28Mn/a2.7×51.1×0.7×−5.5%0.2×n/a
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H · HKEX:8049US$63.16M−US$71.93M1.5×−0.4×−1.4×0.2×25.1%0.0×n/a
Choong Ang Vaccine Laboratory · KRX:072020US$61.86MUS$44.61M10.4×1.2×4.4×0.8×16.6%0.0×n/a
Korea Pharma Co., Ltd. · KRX:032300US$59.92MUS$47.49Mn/a0.7×13.4×1.1×−0.8%0.2×n/a
High Tech Pharm. Co., Ltd. · KRX:106190US$59.61MUS$57.37M6.7×1.1×4.3×0.6×17.2%0.0×n/a
Median of the othersUS$64.35MUS$64.53M8.7×1.1×7.2×0.8×8.9%0.0×

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
45.00 SEK · Analysts' mean
EPS, year to Mar 2027
1.48 · 1 analyst
Revenue, year to Mar 2027
499M · 2 analysts

Team and board

Officers

OfficerRole
Axel SchörlingPresident and CEO
Allan Sylvest AasbergCFO
Martin KristoffersonCOO
Anne Drew JensenChief Sales Officer
Cornelia LindströmChief Regulatory Officer
Ivana AntolašChief Quality Officer
Oskar KarmlidChief Supply Chain Officer

Board

DirectorRole
Christer FåhraeusChairman of the Board
Anders MånssonBoard member
Linda NeckmarBoard member
Niraj KumarBoard member
Per SvangrenBoard member
Raymond de VreBoard member

Events

Results days

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 5, 2026 · Before open+14.3%
Q1 2027Aug 7, 2026 · Before open−7.8%
Q4 2026May 8, 2026 · Before open−42.4%
Q3 2026Feb 3, 2026 · Before open−6.7%
Q2 2026Nov 5, 2025 · Before open−10.3%
Q1 2026Aug 8, 2025 · Before open−4.6%
Q4 2025May 8, 2025 · Before open+7.7%
Q3 2025Feb 5, 2025 · Before open+3.3%
Q2 2025Nov 6, 2024 · Before open+3.0%
Q1 2025Aug 8, 2024 · Before open+7.2%
All 12 quarters
QuarterResultsShare move
Q4 2024May 14, 2024 · After close
Q3 2024Feb 13, 2024 · After close

Open Events

Decks

DeckKindSlidesDate
Q2 2026/27 Earnings PresentationEarnings12 slidesNov 5, 2026
Q1 2026/27 Earnings PresentationEarnings11 slides2026
Investor Day (March 2025)Investor day45 slidesMar 7, 2025
Investor Presentation (January 2025)Investor deck45 slidesJanuary 2025

Open Decks

Financials

Annual, in SEK

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021
Revenue432.7M373.5M264.2M259.9M409.8M179.1M
Cost of revenue269.8M217.6M149.1M144.1M314.0M128.1M
Gross profit162.8M156.0M115.0M115.8M95.7M51.0M
Research and development14.3M11.3M12.1M15.1M9.13M11.7M
Selling, general and administrative102.9M78.5M70.8M59.8M48.2M28.3M
Operating income48.7M67.4M32.6M41.1M38.6M11.2M
Depreciation and amortization23.1M12.5M8.75M14.2M10.3M17.3M
EBITDA71.8M79.9M41.4M55.3M48.8M28.5M
Interest expense30.5M13.0M5.73M2.37M2.87M1.10M
Income before tax18.2M54.4M28.6M39.0M36.0M10.4M
Income tax5.67M11.2M5.90M
Net income12.5M43.1M22.7M30.9M31.5M10.4M
Earnings per share, basic0.421.480.781.061.090.36
Earnings per share, diluted0.421.440.76

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021
Cash and equivalents86.8M82.4M20.5M44.4M41.2M26.6M
Receivables92.7M125.7M58.3M51.7M34.1M21.8M
Inventory200.5M179.0M105.6M65.4M41.7M42.4M
Current assets403.9M400.3M197.8M167.2M123.5M97.8M
Property, plant and equipment5.90M6.32M2.67M
Total assets850.9M808.8M373.8M285.7M237.9M203.5M
Accounts payable70.3M90.9M49.8M29.6M16.0M19.0M
Current liabilities210.2M221.0M162.1M117.2M98.8M94.9M
Long-term debt345.2M341.8M15.5M07.20M12.6M
Total liabilities583.8M587.8M196.0M130.9M114.3M112.3M
Shareholders' equity267.1M221.0M177.7M154.8M123.6M91.2M
Shares outstanding29.5M29.1M29.1M29.1M29.1M29.1M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations28.4M-24.7M-11.4M27.6M41.8M60.0M
Capital spending-5.44M-6.13M-926.0K-20.5M-22.1M-55.6M
Free cash flow22.9M-30.8M-12.4M7.11M19.7M4.47M
Cash from investing-67.2M-245.8M-66.3M
Cash from financing43.2M332.4M53.7M
Change in cash4.36M61.9M-24.0M3.23M14.6M16.3M

Open Financials

Cap table

Built by 6ix from EQL Pharma AB’s releases

Common shares
29,529,610
Fully diluted
29,529,610

Fully diluted

LineShares
Common shares29,529,610

Share count over time

CountShares
Nov 22, 202629,529,610

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Allan Sylvest Aasberg
Chief Financial Officer (CFO)
Buy20,000SEK 26.36SEK 527KAug 14, 2026
Axel Schörling
Chief Executive Officer (CEO)/Managing Directory
Sale24,066SEK 51.30SEK 1.23MMar 27, 2026
Magnus Erreth
Other member of the company's administrative, management or supervisory body
Buy1,000SEK 57.70SEK 57,700Dec 30, 2025
Martin Kristofferson
Other member of the company's administrative, management or supervisory body
Buy19,225SEK 52.27SEK 1MDec 23, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Allan Sylvest AasbergCFO · Since at least Nov 5, 2026
Anders MånssonBoard member · Since at least Nov 5, 2026
Anne Drew JensenChief Sales Officer · Since at least Nov 5, 2026
Axel SchörlingPresident and CEO · Since at least Jul 27, 2026
Christer FåhraeusChairman of the Board · Since at least Nov 5, 2026
Cornelia LindströmChief Regulatory Officer · Since at least Nov 5, 2026
Ivana AntolašChief Quality Officer · Since at least Nov 5, 2026
Linda NeckmarBoard member · Since at least Nov 5, 2026
Martin KristoffersonCOO · Since at least Jul 27, 2026
Niraj KumarBoard member · Since at least Nov 5, 2026
All 13 people
PersonSeat
Oskar KarmlidChief Supply Chain Officer · Since at least Jul 27, 2026
Per SvangrenBoard member · Since at least Nov 5, 2026
Raymond de VreBoard member · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about EQL Pharma AB.